| Index | — | P/E | 23.83 | EPS (ttm) | 1.33 | Insider Own | — | Shs Outstand | 149.79M | Perf Week | 1.47% |
| Market Cap | 4.75B | Forward P/E | 15.22 | EPS next Y | 2.08 | Insider Trans | 0.01% | Shs Float | 147.17M | Perf Month | 39.97% |
| Enterprise Value | 5.80B | PEG | 2.30 | EPS next Q | 0.49 | Short Float | 4.84% | Perf Quarter | 33.77% | ||
| Income | 210.00M | P/S | 0.83 | EPS this Y | 8.80% | Short Ratio | 1.86 | Perf Half Y | 49.91% | ||
| Sales | 5.69B | P/B | 3.77 | EPS next Y | 10.71% | ROA | 6.20% | Short Interest | 7.12M | Perf YTD | -0.53% |
| Book/sh | 8.41 | P/C | 24.47 | EPS next 5Y | 10.35% | ROE | 15.83% | 52W High | 36.80 -13.89% | Perf Year | 20.91% |
| Cash/sh | 1.30 | P/FCF | 13.68 | EPS past 3/5Y | 15.23% — | ROIC | 9.59% | 52W Low | 18.01 75.96% | Perf 3Y | 14.28% |
| Dividend Est. | — | EV/EBITDA | 13.97 | Sales past 3/5Y | 12.72% 13.25% | Gross Margin | 18.17% | Volatility | 0.51% 0.59% | Perf 5Y | 18.07% |
| Dividend TTM | — | EV/Sales | 1.02 | EPS Y/Y TTM | 6.40% | Oper. Margin | 5.94% | ATR (14) | 0.40 | Perf 10Y | 163.21% |
| Dividend Ex-Date | — | Quick Ratio | 0.98 | Sales Y/Y TTM | 5.94% | Profit Margin | 3.68% | RSI (14) | 81.09 | Recom | 2.63 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.47 | EPS Q/Q | 9.76% | SMA20 | 1.34% | Beta | 0.45 | Target Price | 28.31 |
| Payout | 0.00% | Debt/Eq | 0.99 | Sales Q/Q | 1.84% | SMA50 | 18.82% | Rel Volume | 0.68 | Prev Close | 31.83 |
| Employees | 7,397 | LT Debt/Eq | 0.98 | Earnings | Nov 04 | SMA200 | 20.48% | Avg Volume | 3.94M | Price | 31.69 |
| IPO Date | Aug 15, 1996 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.56% 1.60% | Net Debt/EBITDA | 2.53 | Volume | 2,677,316 | Change | -0.44% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | Morgan Stanley | Overweight | $28 → $32 |
| Oct-09-26 | Downgrade | UBS | Buy → Neutral | $39 → $32 |
| Oct-07-26 | Reiterated | Truist Financial | Buy | $30 → $32 |
| Oct-07-26 | Downgrade | Citizens | Market Outperform → Market Perform | |
| Oct-07-26 | Downgrade | Barrington Research | Outperform → Market Perform | |
| Oct-07-26 | Downgrade | William Blair | Outperform → Market Perform | |
| Oct-07-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Oct-07-26 | Downgrade | Jefferies | Buy → Hold | $32 |
| Jul-30-26 | Downgrade | Deutsche Bank | Buy → Hold | $26 → $24 |
| Jul-17-26 | Downgrade | Stephens & Co. | Overweight → Equal Weight | $30 → $24 |
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,693 | 5,650 | 4,998 | 4,302 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4,659 | 4,629 | 3,985 | 3,321 | — | — | — | — | — | |
| Gross Profit | 1,035 | 1,020 | 1,013 | 981 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 675 | 682 | 630 | 607 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 21 | 0 | 61 | 60 | — | — | — | — | — | |
| Operating Income | 339 | 338 | 322 | 315 | — | — | — | — | — | |
| Interest Expense | 58 | 63 | 61 | 62 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 8 | 22 | 106 | — | — | — | — | — | |
| Net Income Before Taxes | 286 | 283 | 284 | 359 | — | — | — | — | — | |
| Income Taxes | 76 | 75 | 72 | 92 | — | — | — | — | — | |
| Consolidated Net Income | 210 | 208 | 212 | 267 | — | — | — | — | — | |
| Net Income From Continuing Operations | 210 | 208 | 212 | 267 | — | — | — | — | — | |
| Net Income | 210 | 208 | 212 | 267 | — | — | — | — | — | |
| EPS (Recurring) | 1.33 | 1.28 | 1.23 | 1.49 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.33 | 1.28 | 1.23 | 1.49 | — | — | — | — | — | |
| EPS (Diluted) | 1.33 | 1.27 | 1.23 | 1.48 | — | — | — | — | — | |
| EBITDA | 415 | 417 | 396 | 472 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 23.83 | 25.09 | 18.86 | 22.76 | — | — | — | — | — | |
| Price To Sales Ratio | 0.86 | 0.91 | 0.80 | 1.40 | — | — | — | — | — | |
| Gross Margin | 18.18 | 18.05 | 20.27 | 22.80 | — | — | — | — | — | |
| Operating Margin | 5.95 | 5.98 | 6.44 | 7.32 | — | — | — | — | — | |
| Net Margin | 3.69 | 3.68 | 4.24 | 6.21 | — | — | — | — | — | |
| Shares Outstanding | 155 | 162 | 172 | 179 | — | — | — | — | — | |
| Market Capitalization | 4,912 | 5,161 | 3,990 | 6,031 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Smyser Collin | GC & Corporate Secretary | May 19 '26 | Option Exercise | 0.00 | 812 | 0 | 75,372 | May 21 |
| SULLIVAN TIMOTHY P | Director | May 07 '26 | Buy | 20.69 | 24,154 | 499,671 | 73,383 | May 07 |
| KRAEMER HARRY M JANSEN JR | Director | May 04 '26 | Buy | 21.41 | 36,610 | 783,773 | 450,000 | May 05 |
| Sethna Meenal | Chief Financial Officer | May 04 '26 | Buy | 20.16 | 16,225 | 327,075 | 98,337 | May 04 |
| RADEMACHER JOHN CHARLES | Chief Executive Officer | May 04 '26 | Buy | 21.18 | 12,500 | 264,706 | 695,152 | May 04 |
| Pate R Carter | Director | Feb 27 '26 | Sale | 32.05 | 30,287 | 970,620 | 11,623 | Mar 03 |
| Bavaro Michael | Chief Human Resources Officer | Feb 27 '26 | Sale | 33.00 | 6,000 | 198,000 | 33,249 | Mar 03 |
| RADEMACHER JOHN CHARLES | Chief Executive Officer | Feb 21 '26 | Option Exercise | 0.00 | 11,087 | 0 | 831,506 | Feb 24 |
| KRAEMER HARRY M JANSEN JR | Director | Nov 03 '25 | Buy | 25.98 | 38,000 | 987,392 | 413,390 | Nov 04 |
| Wright Norman L. | Director | Sep 09 '25 | Buy | 29.31 | 3,411 | 99,976 | 15,501 | Sep 10 |
| SULLIVAN TIMOTHY P | Director | Aug 21 '25 | Buy | 27.51 | 20,000 | 550,200 | 49,229 | Aug 21 |
| GOLDING DAVID W | Director | Aug 21 '25 | Buy | 27.63 | 1,000 | 27,625 | 116,525 | Aug 21 |
| Pate R Carter | Director | Aug 20 '25 | Buy | 27.19 | 750 | 20,391 | 41,910 | Aug 21 |
| KRAEMER HARRY M JANSEN JR | Director | Aug 20 '25 | Buy | 27.15 | 36,000 | 977,278 | 375,390 | Aug 21 |
| Smyser Collin | GC & Corporate Secretary | May 19 '25 | Option Exercise | 0.00 | 11,196 | 0 | 89,715 | May 21 |